COVID Vaccines Put Anti-Science Activists to Shame

On a rain-soaked day, thousands marched on Washington, D.C. to fight for science funding and scientific analysis in politics.

Unsplash

It turns out that, despite the destruction and heartbreak caused by the COVID pandemic, there is a silver lining: Scientists from academia, government, and industry worked together and, using the tools of biotechnology, created multiple vaccines that surely will put an end to the worst of the pandemic sometime in 2021. In short, they proved that science works, particularly that which comes from industry. Though politicians and the public love to hate Big Ag and Big Pharma, everybody comes begging for help when the going gets tough.

The change in public attitude is tangible. A headline in the Financial Times declared, "Covid vaccines offer Big Pharma a chance of rehabilitation." In its analysis, the FT says that the pharmaceutical industry is widely reviled because of the high prices it charges for its drugs, among other things, but the speed with which the industry developed COVID vaccines may allow for its reputation to be refurbished.

Keep Reading Keep Reading
Alex Berezow
Dr. Alex Berezow is a science writer, a U.S./European political affairs writer, and Senior Fellow of Biomedical Science at the American Council on Science and Health. Formerly, he was founding editor of RealClearScience. He has published in numerous outlets, such as BBC, CNN, Wall Street Journal, The Economist, and USA Today, where he serves on the Board of Contributors. He is the author of two books, Little Black Book of Junk Science and Science Left Behind, and holds a PhD in microbiology.
Get our top stories twice a month
Follow us on

Biosensors on a touchscreen are showing promise for detecting arsenic and lead in water.

Photo by Johnny McClung on Unsplash

In 2014, the city of Flint, Michigan switched the residents' water supply to the Flint river, citing cheaper costs. However, due to improper filtering, lead contaminated this water, and according to the Associated Press, many of the city's residents soon reported health issues like hair loss and rashes. In 2015, a report found that children there had high levels of lead in their blood. The National Resource Defense Council recently discovered there could still be as many as twelve million lead pipes carrying water to homes across the U.S.

What if Flint residents and others in afflicted areas could simply flick water onto their phone screens and an app would tell them if they were about to drink contaminated water? This is what researchers at the University of Cambridge are working on to prevent catastrophes like what occurred in Flint, and to prepare for an uncertain future of scarcer resources.

Keep Reading Keep Reading
Hanna Webster
Hanna Webster is a freelance science writer based in San Diego, California. She received a Bachelor’s degree in neuroscience and creative writing in 2018 from Western Washington University, and is now a graduate student in the MA Science Writing program at Johns Hopkins University. She writes stories about neuroscience, biology, and public health. Her essays and articles have appeared in Jeopardy Magazine and Leafly. When Hanna is not writing, she enjoys consuming other art forms, such as photography, poetry, creative nonfiction, and live music

On the left, a Hermès bag made using fine mycelium as a leather alternative, made in partnership with the biotech company MycoWorks; on right, a sheet of mycelium "leather."

Photo credit: Coppi Barbieri and MycoWorks

A natural material that looks and feels like real leather is taking the fashion world by storm. Scientists view mycelium—the vegetative part of a mushroom-producing fungus—as a planet-friendly alternative to animal hides and plastics.

Products crafted from this vegan leather are emerging, with others poised to hit the market soon. Among them are the Hermès Victoria bag, Lululemon's yoga accessories, Adidas' Stan Smith Mylo sneaker, and a Stella McCartney apparel collection.

Keep Reading Keep Reading
Susan Kreimer
Susan Kreimer is a New York-based freelance journalist who has followed the landscape of health care since the late 1990s, initially as a staff reporter for major daily newspapers. She writes about breakthrough studies, personal health, and the business of clinical practice. Raised in the Chicago area, she holds a B.A. in Journalism/Mass Communication and French from the University of Iowa and an M.S. from the Columbia University Graduate School of Journalism.